BCHE and Alzheimer disease: Therefore, these multifunctional α2A-adrenoreceptor antagonists–butyrylcholinesterase inhibitors, such as lead compound 8, introduce an innovative, small molecule, symptomatic as well as disease-modifying treatment option for AD.